Gyre Therapeutics (GYRE) EBITDA Margin Growth (5y) (2015 - 2026)
Gyre Therapeutics (GYRE) EBITDA Margin Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 170,984.00 |
| Mar 31, 2026 | 148,797.00 |
| Dec 31, 2025 | 92,799.00 |
| Sep 30, 2025 | 182,557.00 |
| Jun 30, 2025 | 105,521.00 |
| Mar 31, 2025 | 4,127.00 |
| Mar 31, 2023 | 11.13 Mn |
| Dec 31, 2022 | 181,089.00 |
| Mar 31, 2022 | -31,240.00 |
| Dec 31, 2021 | 650,644.00 |
| Sep 30, 2021 | 414,298.00 |
| Jun 30, 2021 | 274,999.00 |
| Mar 31, 2021 | 266,498.00 |
| Dec 31, 2020 | 336,866.00 |
| Sep 30, 2020 | 176,131.00 |
| Jun 30, 2020 | -79,088.00 |
| Mar 31, 2020 | 42,022.00 |
| Mar 31, 2018 | -11.11 Mn |
| Dec 31, 2017 | 92,291.00 |
| Sep 30, 2017 | -79,400.00 |